Alison Kodjak

Alison Fitzgerald Kodjak is a health policy correspondent on NPR's Science Desk.

Her work focuses on the business and politics of health care and how those forces flow through to the general public. Her stories about drug prices, limits on insurance and changes in Medicare and Medicaid appear on NPR's shows and in the Shots blog.

She joined NPR in September 2015 after a nearly two-decade career in print journalism, where she won several awards—including three George Polk Awards—as an economics, finance, and investigative reporter.

She spent two years at the Center for Public Integrity, leading projects in financial, telecom, and political reporting. Her first project at the Center, "After the Meltdown," was honored with the 2014 Polk Award for business reporting and the Society of Professional Journalists Sigma Delta Chi award.

Her work as both reporter and editor on the foreclosure crisis in Florida, on Warren Buffet's predatory mobile home businesses, and on the telecom industry were honored by several journalism organizations. She was part of the International Consortium of Investigative Journalists team that won the 2015 Polk Award for revealing offshore banking practices.

Prior to joining the Center, Alison spent more than a decade at Bloomberg News, where she wrote about the convergence of politics, government, and economics. She interviewed chairmen of the Federal Reserve and traveled the world with two U.S. Treasury secretaries.

And as part of Bloomberg's investigative team she wrote about the bankruptcy of General Motors Corp. and the 2010 Gulf Oil Spill. She was part of a team at Bloomberg that successfully sued the Federal Reserve to release records of the 2008 bank bailouts, an effort that was honored with the 2009 George Polk Award. Her work on the international food price crisis in 2008 won her the Overseas Press Club's Malcolm Forbes Award.

Fitzgerald Kodjak and co-author Stanley Reed are authors of In Too Deep: BP and the Drilling Race that Took It Down, published in 2011 by John Wiley & Sons.

She's a graduate of Georgetown University and Northwestern University's Medill School of Journalism.

She raises children and chickens in suburban Maryland.

Jessica Stefonik is grinning. She's got a bounce in her step. Her cheeks are a little puffy and her speech is a bit thick.

"It feels weird right now, but I'll get used to it," she says.

What she's trying to get used to is the feeling of having teeth.

On the day we met, Stefonik, a mom of three from Mosinee, Wis., got a set of dentures to replace all of her upper teeth, which she lost over many years to disease and decay.

Stefonik is just 31 years old.

Consumers don't need to use antibacterial soaps, and some of them may even be dangerous, the Food and Drug Administration says.

On Friday, the FDA issued a rule banning the use of triclosan, triclocarban and 17 other chemicals in hand and body washes. which are marketed as being more effective than simple soap.

Summer is winding down, but when members of Congress return to Washington from their vacations next week, many of their constituents want them to do something about the mosquitoes — the ones carrying Zika virus, to be specific.

A new survey shows that three quarters of Americans say Congress should make the allocation of more money to deal with the Zika outbreaks in Florida and Puerto Rico an "important" or "top priority" when they return to Washington.

Treatment for life-threatening allergic reactions is about to get a little cheaper.

Mylan, the maker of the EpiPen, said Monday that it will launch a generic version of the device for half the price of the brand-name product.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

MICHEL MARTIN, HOST:

The EpiPen, an injectable drug that reverses severe allergic reactions, just got a little cheaper for some consumers.

The device's manufacturer, Mylan NV, announced Thursday that it will offer coupons worth as much as $300 off a two-pack.

Editor's note: Updated at 9:20 am ET to include Mylan's announcement that it will reimburse consumers for some of their out-of-pocket costs.

EpiPens are in your friend's purse and your kid's backpack. The school nurse has a few, as does Grandma.

The medicine inside — epinephrine — has been around forever, and the handy gadget that injects it into your leg is not particularly new either.

The U.S. could rein in rising drug prices by being more selective about giving patents to pharmaceutical companies for marginal developments, a study concludes.

That's because brand-name drugs with patents that grant exclusivity account for about 72 percent of drug spending, even though they are only about 10 percent of all prescriptions dispensed, according to the study, published Tuesday in JAMA, the journal of the American Medical Association.

Insurance giant Aetna will stop selling health insurance through most of the exchanges created by the Affordable Care Act in 2017 because the company said it is losing money in many of those markets.

On Monday, Aetna said it will sell individual insurance policies in only 242 counties in four states, down almost 70 percent from the 778 counties in 15 states where the company markets Obamacare plans this year.

The battle continues to rage between drug companies that are trying to make as much money as possible and insurers trying to drive down drug prices. And consumers are squarely in the middle.

That's because, increasingly, prescription insurers are threatening to kick drugs off their lists of approved medications if the manufacturers won't give them big discounts.

Pages